| 早期苦参素联合拉米夫定对乙型肝炎病毒基因变异的影响 |
| |
| 引用本文： | 申悦平,张圆海,王晨红,张莉莉. 早期苦参素联合拉米夫定对乙型肝炎病毒基因变异的影响[J]. 江苏大学学报(医学版), 2005, 15(2): 135-137 |
| |
| 作者姓名： | 申悦平 张圆海 王晨红 张莉莉 |
| |
| 作者单位： | 镇江市第三人民医院内科,江苏,镇江,212000;镇江市第三人民医院内科,江苏,镇江,212000;镇江市第三人民医院内科,江苏,镇江,212000;镇江市第三人民医院内科,江苏,镇江,212000 |
| |
| 基金项目： | 镇江市科技基金资助项目(SG2001100) |
| |
| 摘 要： | 目的:探讨早期苦参素联合拉米夫定(贺浦丁)治疗慢性肝炎YMDD变异的影响。方法:119例患者被随机分为观察组62例,给予贺浦丁100mg/d,口服2年,同时加用苦参素600mg/d,iv,2个月,后600mg/d,口服4个月;对照组57例单用拉米夫定100mg/d,口服2年。结果:疗程结束时(2年),观察HBV-YMDD变异率、HBeAg转换率的变化。两组患者HBeAg血清转换率分别为38.7%和19.2%,HBV-YMDD变异率分别为21.0%和33.3%,观察组疗效明显优于对照组(P<0.01)。结论:苦参素联合拉米夫定能够显著提高HbeAg血清转换率,降低HBV-YMDD变异发生率,建议二者早期联合应用以作为慢性乙型肝炎的一种治疗方案,更深入的研究,待进一步验证。
|
| 关 键 词： | 苦参素 拉米夫定 YMDD变异 |
| 文章编号： | 1671-7783(2005)02-0135-03 |
| 修稿时间： | 2004-12-14 |
Clinical Function on YMDD by Oxymatrine Combination with Lamivudine |
| |
| SHEN Yue-ping,ZHANG Yuan-hai,WANG Chen-Hong,ZHANG Li-li. Clinical Function on YMDD by Oxymatrine Combination with Lamivudine[J]. Journal of Jiangsu University Medicine Edition, 2005, 15(2): 135-137 |
| |
| Authors: | SHEN Yue-ping ZHANG Yuan-hai WANG Chen-Hong ZHANG Li-li |
| |
| Abstract: | Objective: To study the influence of oxymatrine combination with lamivudine in treating chronic hepatitis B. Methods: All of 119 patients were randomly divided into 2 groups, 62 patients as a treatment group received 100 mg/d,po,lamivudine combination with 600 mg/d,po,iv,2 mouths, then 600 mg/d,po, 4 mouths;57 patients as a control group was treated only with lamivudine 100 mg/d,po. Results: After completion of therapy (2 years),the mutation rate of YMDD and the negative rate of HbeAg was observed.In the two groups,the negative rate of HbeAg was 38.7%and 19.2%.The mutation rate of YMDD was 21.0%and 33.3%,the efficany of the treatment group was higher than that of control group(P<0.01). Conclusion: oxgmatrine combination with lamivudine can improve the negative rate of HBeAg and reduse the mutation rate of YMDD. |
| |
| Keywords: | Oxgmatrine Lamivudine YMDD mutation |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
